

**NERVGEN PHARMA CORP.****Condensed Consolidated Interim Statements of Financial Position**

(Expressed in Canadian dollars)

(Unaudited)

as at

**September 30, 2019****December 31, 2018**

\$

\$

**Assets****Current assets**

Cash	<b>6,272,575</b>	2,474,340
Accounts receivable	<b>100,341</b>	25,843
Prepays and deposits (Notes 6, 11)	<b>168,037</b>	49,375
	<b>6,540,953</b>	2,549,558

**Non-current assets**

Intangible assets (Note 7)	<b>519,164</b>	547,829
	<b>519,164</b>	547,829
	<b>7,060,117</b>	3,097,387

**Liabilities****Current liabilities**

Accounts payable and accrued liabilities (Note 8)	<b>418,056</b>	390,802
Due to related parties (Note 11)	<b>155,489</b>	58,074
	<b>573,545</b>	448,876

**Non-current liabilities**

License fee payable (Note 7)	-	134,230
	-	134,230
	<b>573,545</b>	583,106

**Shareholders' Equity**

Common shares (Note 9)	<b>13,331,171</b>	3,846,630
Reserves (Note 10)	<b>1,403,595</b>	37,947
Deficit	<b>(8,248,194)</b>	(1,370,296)
	<b>6,486,572</b>	2,514,281
	<b>7,060,117</b>	3,097,387

Nature of business (Note 1)

Subsequent events (Note 13)

Approved by the Board

/s/ William J. Radvak Director/s/ Brian E. Bayley Director